Squadron Capital Management LLC holds a focused book of 30 stocks worth $250.0M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Nektar Therapeutics and trimmed Abivax Sa-ADR. Their largest long position is Relmada Therapeutics Inc at 24% of the equity book. They also disclosed $8.2M in put options (a bearish bet) and $14.8M in call options (bullish), shown separately below and excluded from the equity book.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
96% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Squadron Capital Management LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| UBS Group AG | 41 / 30 | $873.3M |
| MORGAN STANLEY | 38 / 30 | $990.4M |
| GEODE CAPITAL MANAGEMENT, LLC | 36 / 30 | $765.1M |
| BlackRock, Inc. | 34 / 30 | $2.6B |
| MILLENNIUM MANAGEMENT LLC | 33 / 30 | $663.6M |
| Ken Griffin | 33 / 30 | $624.0M |
| JPMORGAN CHASE & CO | 31 / 30 | $385.3M |
| ROYAL BANK OF CANADA | 31 / 30 | $19.1M |
Ranked by how many of Squadron Capital Management LLC's top 30 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Relmada Therapeutics Inc COM | $59.0M | 8.47M | 23.6% | ▲+26% Added · +1.8M sh | |
| 2 | Cogent Biosciences Inc COM | $30.3M | 787.5K | 12.1% | ▲+1.0% Added · +7K sh | |
| 3 | Kalvista Pharmaceuticals Inc COM | $19.8M | 985.1K | 7.9% | ▲+41% Added · +285K sh | |
| 4 | Kodiak Sciences Inc COM | $14.5M | 380.0K | 5.8% | ▲+30% Added · +88K sh | |
| 5 | Abivax Sa SPONSORED ADS | $14.5M | 130.0K | 5.8% | ▼−10% Reduced · −15K sh | |
| 6 | Edgewise Therapeutics Inc COM | $11.0M | 350.0K | 4.4% | —Held | |
| 7 | Nektar Therapeutics COM NEW | $9.0M | 125.0K | 3.6% | ▲New New position | |
| 8 | Adlai Nortye Ltd SPONSORED ADS | $8.8M | 1.27M | 3.5% | ▲New New position | |
| 9 | Zentalis Pharmaceuticals Inc COM | $8.5M | 3.63M | 3.4% | ▲New New position | |
| 10 | Maze Therapeutics Inc COM | $7.7M | 257.5K | 3.1% | ▼−47% Reduced · −233K sh | |
| 11 | Scynexis Inc COM NEW | $7.0M | 7.61M | 2.8% | ▲New New position | |
| 12 | Relay Therapeutics Inc COM | $6.7M | 672.5K | 2.7% | ▲New New position | |
| 13 | C4 Therapeutics Inc COM STK | $5.9M | 2.25M | 2.4% | ▲New New position | |
| 14 | Inhibikase Therapeutics Inc COM NEW | $5.9M | 3.50M | 2.4% | ▼−17% Reduced · −725K sh | |
| 15 | Palisade Bio Inc COM | $5.3M | 3.00M | 2.1% | ▼−33% Reduced · −1.5M sh | |
| 16 | Eupraxia Pharmaceuticals Inc COM | $4.9M | 680.0K | 2.0% | ▲+36% Added · +180K sh | |
| 17 | GH Research PLC ORDINARY SHARES | $4.6M | 325.0K | 1.8% | ▲+3.2% Added · +10K sh | |
| 18 | Promis Neurosciences Inc COM SHS | $4.1M | 325.0K | 1.7% | ▲New New position | |
| 19 | Lipocine Inc New COM NEW | $3.6M | 450.0K | 1.4% | ▼−15% Reduced · −80K sh | |
| 20 | Inventiva Sa ADS | $3.0M | 535.0K | 1.2% | ▲+78% Added · +235K sh | |
| 21 | Alx Oncology Hldgs Inc COM | $2.9M | 1.46M | 1.2% | ▲New New position | |
| 22 | Context Therapeutics Inc COM | $2.9M | 1.10M | 1.2% | ▲New New position | |
| 23 | Nextcure Inc COM NEW | $2.8M | 265.0K | 1.1% | ▲+12% Added · +28K sh | |
| 24 | Sol-Gel Technologies Ltd SHS NEW | $2.5M | 31.0K | 1.0% | ▲New New position | |
| 25 | Pasithea Therapeutics Corp COM NEW | $1.6M | 2.10M | 0.6% | —Held | |
| 26 | Traws Pharma Inc COM NEW | $936K | 511.7K | 0.4% | ▼−28% Reduced · −202K sh | |
| 27 | Therapeuticsmd Inc COM NEW | $849K | 420.4K | 0.3% | ▲New New position | |
| 28 | Spruce Biosciences Inc COM NEW | $797K | 12.2K | 0.3% | ▼−83% Reduced · −58K sh | |
| 29 | Werewolf Therapeutics Inc COM | $469K | 563.5K | 0.2% | ▲New New position | |
| 30 | Neuphoria Therapeutics Inc COM | $312K | 76.7K | 0.1% | ▲New New position |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2050709/holdings"
Use Arkolith to show Squadron Capital Management LLC's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | KALVISTA PHARMACEUTICALS INCKALV | $6.3M | 315K |
| PUT · bearish | KARYOPHARM THERAPEUTICS INCKPTI | $4.2M | 750K |
| PUT · bearish | IDEAYA BIOSCIENCES INCIDYA | $4.0M | 120K |
| CALL · bullish | IDEAYA BIOSCIENCES INCIDYA | $3.5M | 104K |
| CALL · bullish | ARRIVENT BIOPHARMA INCAVBP | $2.5M | 110K |
| CALL · bullish | RELAY THERAPEUTICS INCRLAY | $1.5M | 150K |
| CALL · bullish | ZENTALIS PHARMACEUTICALS INCZNTL | $936K | 400K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.